作者
Maria Fleseriu, Dagmar Führer-Sakel, Aart J van der Lely, Laura De Marinis, Thierry Brue, Joli van Der Lans-Bussemaker, Judith Hey-Hadavi, Cecilia Camacho-Hubner, Michael P Wajnrajch, Srinivas Rao Valluri, Andrew Anthony Palladino, Roy Gomez, Roberto Salvatori
发表日期
2021/10
来源
European journal of endocrinology
卷号
185
期号
4
页码范围
525-538
出版商
Oxford University Press
简介
Objective
To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY.
Design
Global (15 countries), multicentre, non-interventional study (2004–2017).
Methods
The complete ACROSTUDY cohort comprised patients with acromegaly, who were being treated with pegvisomant (PEGV) prior to the study or at enrolment. The main endpoints were long-term safety (comorbidities, adverse events (AEs), pituitary tumour volumes, liver tests) and efficacy (IGF1 changes).
Results
Patients (n = 2221) were treated with PEGV for a median of 9.3 years (range, 0–20.8 years) and followed up for a median of 7.4 years (range, 0–13.9 years). Before PEGV, 96.3% had received other acromegaly treatments (surgery/radiotherapy/medications). Before PEGV treatment, 87.2% of …
学术搜索中的文章
M Fleseriu, D Führer-Sakel, AJ van der Lely… - European journal of endocrinology, 2021